Replies to post #177075 on Biotech Values

[DewDiligence]

VRX/AGN addendum: If this deal were to be consummated, VRX would have to divest the US rights to Dysport because it’s the main competitor to Botox. This in itself isn’t a big deal, however, since Dysport is an inferior product (IMO) and a very distant #2.

[DewDiligence]

AGN again sets all-time highs ($183.51 intra-day; $183.34 close).

Still hoping that merger with VRX does not occur.